What are the symptoms and treatment options for Legionnaires' disease?

Symptoms of Legionnaires' Disease

Legionnaires' disease presents as pneumonia with high fever, cough, dyspnea, and sputum production, but cannot be reliably distinguished from other pneumonias based on clinical features alone. 1

Cardinal Respiratory Symptoms

• Cough is a primary symptom, typically dry initially, though sputum production may develop 1, 2
• Dyspnea (shortness of breath) occurs as the pneumonia progresses 1
• Pleuritic chest pain is characteristic and frequently reported 2
• Rales and altered breath sounds may be detected on physical examination, though these findings are neither sensitive nor specific 1

Fever Pattern

• High-grade fever is a hallmark feature, typically persistent and severe 1, 2
• Relative bradycardia (pulse-temperature dissociation) is characteristic, where the heart rate is lower than expected for the degree of fever 2
• Chills commonly accompany the fever 2

Gastrointestinal Manifestations

• Diarrhea is a distinctive feature that helps differentiate Legionnaires' disease from other pneumonias 2
• Gastrointestinal symptoms occur more frequently than in typical bacterial pneumonias 3

Neurological Symptoms

• Confusion and altered mental status can occur, particularly in severe cases 1
• Encephalopathy may develop as a central nervous system manifestation 1

Laboratory Abnormalities

• Hyponatremia (low sodium levels) is a suggestive laboratory finding that should raise suspicion for Legionnaires' disease 1
• Elevated lactate dehydrogenase (LDH) levels may be present 1
• Elevated aspartate aminotransferase (AST) to alanine transaminase (ALT) ratio can occur, sometimes mimicking alcoholic hepatitis 3
• Markedly elevated C-reactive protein (CRP) with relatively preserved white blood cell count initially, followed by leukopenia, fits the pattern seen in Legionella 1

Radiographic Findings

• Nodular consolidation with ground-glass opacities can be seen on CT imaging 1
• Minimal respiratory symptoms despite significant radiographic findings is consistent with the atypical presentation that can occur 1

Severity Indicators and Outcomes

• Mortality rates range from 5-25% in immunocompetent hosts 1
• Mortality reaches 40% in ICU patients, immunocompromised patients, or those with nosocomial infection 1, 4
• Multiorgan failure can develop in immunosuppressed patients or severe cases 3
• Severe lung injury requiring respiratory and/or hemodynamic support occurs in critical cases 4

High-Risk Populations

• Immunosuppressed patients, including transplant recipients, those with hematologic malignancy, or end-stage renal disease are at markedly increased risk 5, 1
• Advanced age (>60-65 years) increases risk 5, 1
• Smokers are at moderately increased risk 5, 1
• Patients with diabetes, chronic lung disease (COPD), or congestive heart failure have elevated risk 5, 1

Environmental Exposure History

• Recent travel with overnight stay outside the home should raise suspicion 1
• Exposure to spas, hot tubs, or cooling towers is a key risk factor 1
• Recent changes in domestic plumbing may indicate exposure 1

---

Treatment of Legionnaires' Disease

Fluoroquinolones (particularly levofloxacin 750 mg daily) or macrolides (particularly azithromycin) are the preferred first-line treatments, with fluoroquinolones showing more rapid clinical response and fewer complications. 6

First-Line Antibiotic Therapy

For Hospitalized Patients (Non-ICU)

• Levofloxacin 750 mg IV/PO daily is the preferred fluoroquinolone 6
• Moxifloxacin 400 mg IV/PO daily is an alternative fluoroquinolone option 6, 7
• Azithromycin 1000 mg IV on day 1, then 500 mg IV/PO daily is the preferred macrolide 6, 7
• Early switch to oral therapy (within 2-4 days) is safe once clinical stability is achieved 6

For Severe/ICU Cases

• Intravenous fluoroquinolones are first choice for severe disease or immunocompromised hosts 6, 8
• Levofloxacin 750 mg IV daily is preferred due to rapid clinical response and superior outcomes in severe disease with complications 7
• Adding rifampin to the primary regimen should be considered for severely ill patients with significant comorbidities or immunocompromised hosts 6

For Non-Hospitalized Patients

• Levofloxacin 750 mg PO daily is the preferred oral fluoroquinolone 6
• Azithromycin 500 mg PO on day 1, then 250 mg PO daily is the preferred oral macrolide 6
• Clarithromycin 500 mg PO twice daily is an alternative macrolide 6
• Doxycycline 100 mg PO twice daily is another option 6

Duration of Treatment

• Standard duration is 7-10 days for immunocompetent patients 6
• Extended duration of 14-21 days is recommended for immunocompromised patients or when acute kidney injury is present 6, 7

Comparative Efficacy

• Fluoroquinolones are associated with more rapid defervescence, fewer complications, and shorter hospital stays compared to macrolides 6, 7, 8
• Fluoroquinolones demonstrate superior outcomes in severe disease with acute kidney injury 7

Critical Treatment Principles

• Treatment should be initiated as rapidly as possible, as delay is associated with increased mortality 6, 9
• Do not delay antimicrobial therapy while awaiting diagnostic confirmation 7
• Beta-lactam antibiotics are completely ineffective against Legionella and should never be used as monotherapy 6, 7
• Erythromycin is the historical drug of choice, though newer macrolides and fluoroquinolones are now preferred 2

Diagnostic Testing to Guide Treatment

• Legionella pneumophila serogroup 1 urinary antigen test is the most clinically useful rapid diagnostic test, positive in >80% of L. pneumophila serogroup 1 infections 1, 8
• Sputum culture on selective media can detect all Legionella species and serogroups, though takes longer 1, 2
• Testing for Legionella should be performed at hospital admission for severe community-acquired pneumonia 5, 9
• Both culture and urine antigen test should be performed on suspected cases 5

Supportive Care for Severe Cases

• Aggressive intravenous fluid repletion is essential, especially when complicated by rhabdomyolysis 7
• Monitor serum creatinine, CPK levels, electrolytes, and urine output daily in severe cases 7
• Strictly avoid all nephrotoxic medications during acute and recovery phases, as each additional nephrotoxin more than doubles the risk of acute kidney injury progression 7
• Discontinue NSAIDs, which present 53% greater odds of worsening acute kidney injury 7

Common Pitfalls to Avoid

• Do not underestimate severity based on initial presentation, as mortality rates reach 40% in ICU patients and those with renal complications 7
• Macrolide resistance is increasing in some regions, which may affect treatment efficacy 6
• Rifampin combination therapy should be reserved for severe cases or immunocompromised patients, not used routinely 6
• Inadequate or delayed antibiotic treatment has been associated with worse prognosis 9